Navigation Links
Aspirin: Scientists believe cancer prevention benefits outweigh harms
Date:8/5/2014

New research from Queen Mary University of London (QMUL) reveals taking aspirin can significantly reduce the risk of developing and dying from the major cancers of the digestive tract, i.e. bowel, stomach and oesophageal cancer.

For the first time, scientists have reviewed all the available evidence from many studies and clinical trials assessing both the benefits and harms of preventive use of aspirin. Conclusions of the study, funded by Cancer Research UK among others, are published today in the leading cancer journal Annals of Oncology*.

The researchers, led by Professor Jack Cuzick, Head of QMUL's Centre for Cancer Prevention (London, UK), found taking aspirin for 10 years could cut bowel cancer cases by around 35% and deaths by 40%. Rates of oesophageal and stomach cancers were cut by 30% and deaths from these cancers by 35-50%.

To reap the benefits of aspirin, the evidence shows people need to start taking a daily dose of 75-100 mg for at least five years and probably 10 years between the ages of 50 and 65. No benefit was seen whilst taking aspirin for the first three years, and death rates were only reduced after five years.

However, the research also warns taking aspirin long-term increases the risk of bleeding from the digestive tract, e.g. stomach bleeding. Amongst 60-year-old individuals who take daily aspirin for 10 years, the risk of digestive tract bleeds increases from 2.2% to 3.6%, and this could be life-threatening in a very small proportion (less than 5%) of people.

Overall, rates of serious or fatal gastrointestinal bleeding are very low under the age of 70, but increased sharply after that age. Another side effect of aspirin use is peptic ulcer, the risk of which is increased by 30-60%.

The study also uncovers uncertainty over the most appropriate dose of aspirin required to maximize the benefit / harm ratio, with doses varying between 75 mg to 325mg a day in different clinical trials and studies. It is also not clear whether taking aspirin for longer than 10 years will result in greater benefits.

Professor Jack Cuzick, Queen Mary University of London, comments: "It has long been known that aspirin one of the cheapest and most common drugs on the market can protect against certain types of cancer. But until our study, where we analysed all the available evidence, it was unclear whether the pros of taking aspirin outweighed the cons.

"Whilst there are some serious side effects that can't be ignored, taking aspirin daily looks to be the most important thing we can do to reduce cancer after stopping smoking and reducing obesity, and will probably be much easier to implement."

"Our study shows that if everyone aged between 50-65 started taking aspirin daily for at least 10 years, there would be a 9% reduction in the number of cancers, strokes and heart attacks overall in men and around 7% in women. The total number of deaths from any cause would also be lower, by about 4% over a 20-year period. The benefits of aspirin use would be most visible in the reduction in deaths due to cancer.

"The risk of bleeding depends on a number of known factors which people need to be aware of before starting regular aspirin and it would be advisable to consult with a doctor before embarking on daily medication."

Further research is now needed to define more clearly who will benefit most greatly from taking aspirin and who is most at risk of the bleeding side effects.


'/>"/>

Contact: Charli Scouller
c.scouller@qmul.ac.uk
020-788-27943
Queen Mary, University of London
Source:Eurekalert

Related medicine news :

1. Scientists Shed Light on Link Between Depression, Dementia
2. Scientists pinpoint bladder cancer patients who could benefit from tumor-softening treatment
3. Scientists to study hereditary breast cancer to find BRCA1 treatment
4. Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells
5. Scientists test nanoparticle alarm clock to awaken immune systems put to sleep by cancer
6. Brain Tumor Causes and Risk Factors Elude Scientists
7. Brain tumor causes and risk factors elude scientists
8. Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date
9. NIH-supported scientists demonstrate very early formation of SIV reservoir
10. Scientists Snipped HIV Out of Human DNA
11. Scientists Discover New Way to Make Human Platelets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... further expand its existing adherence automation lines. The ATP® Mini and InspectRx® ... technology of TCG’s standard products, but at a size and price point that ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... since 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, a ... major international travel insurance products online, under their own brand. The online marketplace ...
(Date:7/20/2017)... ... 2017 , ... A local summer theatre camp is celebrating ... support fine arts programs in Chester County’s Elementary Schools. In late June, students ... , More than 850 people attended the two performances, an increase from ...
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... Med Tech ... the Minnesota based Health IT business unit of Constellation Inc., a move that will ... established base of operations in St. Louis, the acquisition is expected to help ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th ... weight loss surgery patients who had received a body contouring procedure reported experiencing a ... clinic Beverly Hills Physicians (BHP), which provides both types of procedures, notes that this ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... July 13, 2017  Centurion Medical Products, a leader in medical ... ® fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are ... help alleviate patient pain while preventing unneeded emergency department admission due ...
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
(Date:7/11/2017)... July 11, 2017  Sysmex America, Inc., a ... testing equipment as well as middleware information systems ... to make quality assurance easier and more risk ... well known for the innovation that it delivers ... elevates quality assurance processes to a new level ...
Breaking Medicine Technology: